Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 3:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,122 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Prevention Clear all
Completed Phase 3 Interventional Results available

A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.

NCT00601172
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant, Dexamethasone, Placebo, Ondansetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
23
States / cities
Hot Springs, Arkansas • Corona, California • Fountain Valley, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 25, 2026, 3:53 AM EDT
Completed Not applicable Interventional Results available

The CONTRoL Trial: Cryotherapy vs. cOmpression Neuropathy TRiaL

NCT03873272
View directory record Official record
Conditions
CIPN - Chemotherapy-Induced Peripheral Neuropathy
Interventions
Cryotherapy, Compression Therapy, Loose glove/sock
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 99 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 25, 2026, 3:53 AM EDT
Recruiting Phase 2 Interventional

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

NCT04098744
View directory record Official record
Conditions
CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia, HPV Related Disease
Interventions
Artesunate vaginal insert, Placebo vaginal insert
Drug
Lead sponsor
Frantz Viral Therapeutics, LLC
Industry
Eligibility
25 Years to 100 Years · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Fort Myers, Florida • Ann Arbor, Michigan • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 25, 2026, 3:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

S0000 Selenium and Vitamin E in Preventing Prostate Cancer

NCT00006392
View directory record Official record
Conditions
Prostate Cancer
Interventions
Vitamin E, Selenium, Vitamin E placebo, selenium placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
50 Years to 120 Years · Male only
Enrollment
35,533 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2012
U.S. locations
13
States / cities
Chicago, Illinois • Joliet, Illinois • Maywood, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 25, 2026, 3:53 AM EDT
Completed Phase 2 Interventional

Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies

NCT01056614
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Hematopoietic/Lymphoid Cancer, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia
Interventions
fludarabine phosphate, busulfan, anti-thymocyte globulin, tacrolimus, methotrexate, peripheral blood stem cell transplantation, allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 25, 2026, 3:53 AM EDT
Completed Not applicable Interventional

Rural Women Connecting for Better Health

NCT01441011
View directory record Official record
Conditions
Breast Cancer, Obesity
Interventions
Group phone counseling, Newsletter
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
Up to 75 Years · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 25, 2026, 3:53 AM EDT
Completed Phase 1 Interventional

Calcium and Magnesium Infusion for the Prevention of Taxane Induced Neuropathy

NCT01682499
View directory record Official record
Conditions
Paclitaxel-induced Neuropathy
Interventions
calcium gluconate and magnesium sulfate
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 25, 2026, 3:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Feasibility of the Management of Severe Cervical Dysplasia in a Single Visit

NCT00237562
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
Large loop electrosurgical excision
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 5, 2006 · Synced Oct 25, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

NCT04017962
View directory record Official record
Conditions
CMV, CMV Infection, Hematopoietic Cell Transplant
Interventions
Letermovir Pill, blood draw
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 25, 2026, 3:53 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Sexual Health Empowerment for Women's Health

NCT03984695
View directory record Official record
Conditions
Cervical Cancer, Breast Cancer, Contraceptive Usage, Sexually Transmitted Diseases
Interventions
SHE-WOMEN
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
279 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 25, 2026, 3:53 AM EDT
Completed Phase 1 Interventional

Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants

NCT00001830
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Graft vs Host Disease, Hodgkin's Disease, Multiple Myeloma, Non Hodgkin's Lymphoma
Interventions
Th2 cells in allo HSCTT, Th2 Cells
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 25, 2026, 3:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patient Navigation for Lung Cancer Screening in an Urban Safety-Net System

NCT02758054
View directory record Official record
Conditions
Non-Small Cell Lung Carcinoma, Compliance Behavior, Prevention Harmful Effects
Interventions
Patient Navigation
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
55 Years to 74 Years
Enrollment
447 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 25, 2026, 3:53 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients

NCT05699603
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Biopsy, Calcipotriene, Fluorouracil
Procedure · Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
4
States / cities
Tucson, Arizona • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 25, 2026, 3:53 AM EDT
Completed Not applicable Interventional Results available

Dalteparin in Preventing DVT in Participants With Cancer

NCT00525057
View directory record Official record
Conditions
Bone Sarcoma, Femur Fracture, Lymphoma, Metastatic Neoplasm, Pathologic Fracture, Plasma Cell Myeloma, Soft Tissue Sarcoma
Interventions
Dalteparin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 25, 2026, 3:53 AM EDT
Recruiting Phase 4 Interventional

Apixaban or Enoxaparin After Head and Neck Cancer Surgery

NCT07189897
View directory record Official record
Conditions
Venous Thromboembolism, Head and Neck Cancer
Interventions
Enoxaparin, Apixaban
Drug
Lead sponsor
Kiranya Arnold
Other
Eligibility
18 Years to 89 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 25, 2026, 3:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants

NCT04595513
View directory record Official record
Conditions
Tuberous Sclerosis Complex, Epilepsy
Interventions
TAVT-18 (sirolimus)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Day to 6 Months
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 25, 2026, 3:53 AM EDT
Withdrawn Phase 2 Interventional

Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma

NCT03719560
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Methotrexate, Cytarabine
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 25, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Results available

Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation

NCT02458235
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions
azacitidine, donor lymphocyte infusion
Drug · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 29 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 25, 2026, 3:53 AM EDT
Not yet recruiting Phase 2 Interventional

Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer

NCT07499999
View directory record Official record
Conditions
Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia, BRCA2 Mutation, CHEK2 Gene Mutation, Ataxia Telangiectasia Mutated Gene Mutation
Interventions
Exemestane, Tamoxifen
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 25, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Results available

PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery

NCT03084536
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Cancer of Breast
Interventions
Bupivacaine, Gabapentin, Celecoxib, Acetaminophen, Midazolam, Fentanyl
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 25, 2026, 3:53 AM EDT
Not listed Not applicable Interventional

Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

NCT00093587
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 25, 2026, 3:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Research in Ethno-Medicine and Education (REMED)

NCT05907187
View directory record Official record
Conditions
Cervical Cancer, Human Papilloma Virus, HPV, Human Papillomavirus Infection
Interventions
Cervical Cancer Prevention Education
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 25, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Results available

Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer

NCT04033419
View directory record Official record
Conditions
Cognitive Decline, Chemo-brain
Interventions
Memantine
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 25, 2026, 3:53 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Community Outreach-based Study to Increase Cervical Cancer Screening Among Hispanic Women in Cleveland

NCT05470309
View directory record Official record
Conditions
Cervical Cancer
Interventions
Not listed
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
30 Years to 65 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 25, 2026, 3:53 AM EDT